With modern cancer therapeutics changing the landscape of cancer treatment, the need to address cardiovascular treatment-related complications is increasingly important. A new ACC Concise Clinical Guidance report on the Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies addresses this need by focusing on three classes of anticancer therapies: Bruton's tyrosine kinase inhibitors, immune checkpoint inhibitors, and vascular endothelial growth factor inhibitors. Read more.